Dr. Dhanish Joseph, an Associate Professor in the Department of Pharmaceutics at Nirmala College of Pharmacy, unveils a groundbreaking development in pharmaceuticals. As the founder of NovelD, Dr. Joseph spearheads a team dedicated to revolutionising drug delivery systems.
Enhancing Bioavailability
At the core of NovelD’s innovation lies a multilayered tablet formulation combining Atorvastatin with Naringin. Atorvastatin, renowned for its efficacy in cholesterol management, often faces limitations due to its low bioavailability – only 4% of the administered dose reaches the bloodstream, rendering much of the medication ineffective.
Addressing the Challenge
Driven by the desire to optimise drug efficacy while minimising costs and side effects, Dr. Joseph and his team embarked on a journey to enhance Atorvastatin’s bioavailability. Through meticulous research and experimentation, they identified Naringin, a flavonoid abundant in grapefruit, as a potential solution.
The Breakthrough Solution
By formulating Atorvastatin and Naringin into a single tablet, NovelD achieved a remarkable enhancement in bioavailability. This innovative approach ensures that a significantly higher percentage of the drug reaches the bloodstream, thereby maximising therapeutic effects while minimising dosage requirements.
Transforming Patient Care
The implications of NovelD’s breakthrough are profound. Patients now have access to a more cost-effective treatment option with reduced dosage requirements. By minimising the side effects associated with Atorvastatin and optimising therapeutic outcomes, NovelD’s innovation promises to revolutionise patient care in cholesterol management.
Dr. Dhanish Joseph’s visionary approach and NovelD’s groundbreaking innovation mark a paradigm shift in pharmaceutical research and development. By addressing the fundamental challenges in drug delivery, NovelD paves the way for a future where healthcare is more effective, accessible, and patient-centric.
